Search / Trial NCT00000966

A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS

Launched by PFIZER · Aug 30, 2001

Trial Information

Current as of December 14, 2024

Completed

Keywords

Toxoplasmosis Toxoplasma Pyrimethamine Leucovorin Drug Evaluation Drug Therapy, Combination Encephalitis Administration, Oral Acquired Immunodeficiency Syndrome Azithromycin

ClinConnect Summary

Encephalitis caused by Toxoplasma gondii is the most frequent cause of focal central nervous system infection in patients with AIDS. Untreated, the encephalitis is fatal. Standard treatment for toxoplasmic encephalitis is associated with serious adverse effects. Thus, alternative treatments are needed.

Patients with toxoplasmosis are given azithromycin at doses starting at the lowest dose for the first cohort, an intermediate dose for the second cohort, and a higher dose for the third cohort. Subsequent cohorts may receive azithromycin in increased dosage, if needed to determine the MTD. A...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia (PCP).
  • * Allowed during maintenance period (weeks 7 - 24):
  • Zidovudine and other antiretrovirals available through treatment IND mechanisms, ganciclovir, and maintenance doses of amphotericin (other investigational therapies require permission from the study chair), steroids for the treatment of acute PCP.
  • Isoniazid (INH) only for patients already on INH.
  • Patients must have the following:
  • HIV infection or belong to high-risk group. Presumptive or definite diagnosis of toxoplasmic encephalitis.
  • Each patient, or his/her appropriate family member, or legal designee must be able to understand and sign a written informed consent, in accordance with the local practices at each site.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following conditions or symptoms are excluded:
  • History of cerebral toxoplasmosis or toxoplasmosis infection in any other organ or tissue.
  • Coma.
  • More than 72 hours of treatment for current episode of toxoplasmic encephalitis prior to study entry.
  • Central nervous system (CNS) lymphoma.
  • Cerebral Kaposi's sarcoma.
  • Active hepatitis or clinical jaundice.
  • History of serious hypersensitivity or intolerance to any of the study drugs.
  • Serum or cerebrospinal fluid (CSF) positive for cryptococcus antigen or culture.
  • Malignancies requiring use of cytotoxic chemotherapy.
  • Inability to take oral therapy reliably.
  • Malabsorption syndrome.
  • Concurrent Medication:
  • Excluded:
  • Opportunistic infection requiring either acute treatment or maintenance therapy with azithromycin, erythromycin or other macrolides, sulfonamides, amphotericin, dapsone, ganciclovir, antifolates, and other investigational agents except erythropoietin. For first 6 weeks of treatment, patients may not receive treatment with erythromycin (or other macrolides), sulfonamides, immunomodulators with the exception of alpha interferon, lymphocyte replacement, cytotoxic chemotherapy, dapsone, ganciclovir, rifampicin, coumadin, antiretrovirals, and investigational agents other than erythropoietin.
  • Patients with the following are excluded:
  • Negative HIV antibodies by a federally licensed ELISA, unless there is documentation of a previously positive HIV culture or p24 antigen.
  • Infections of the central nervous system.
  • Malignancies requiring the use of cytotoxic chemotherapy.
  • Any medical or social condition that, in the opinion of the investigator, would adversely affect participation and/or compliance in this study.

Trial Officials

Luft B

Study Chair

Remington J

Study Chair

About Pfizer

Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.

Locations

Los Angeles, California, United States

Bronx, New York, United States

New York, New York, United States

West Columbia, South Carolina, United States

Worcester, Massachusetts, United States

New York, New York, United States

Miami, Florida, United States

Bronx, New York, United States

East Meadow, New York, United States

Stony Brook, New York, United States

Bronx, New York, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials